^
Association details:
| Biomarker: | FGFR2 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | HMPL-453 (FGFR1 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Excerpt:
...Patients with histologically or cytologically confirmed locally advanced unresectable or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements; 4....
Trial ID:
Source:
Title:
A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.
Published date:
05/25/2023
Excerpt:
Pts with histologically or cytologically confirmed locally advanced or metastatic iCCA with FGFR2 fusions...Of 22 evaluable pts...the best overall response by investigator assessment was confirmed partial response in seven (31.8%) pts and stable disease in an additional 12 pts (54.5%), resulting in a disease control rate (DCR) of 86.4%. Specifically, in cohort 2 the confirmed ORR was 50% (95% CI, 18.7%–81.3%) and DCR was 90% (95% CI, 55.5%–99.7%)...HMPL-453 showed promising efficacy, particularly in RP2D regimen (300 mg, QD, 2w on/1w off) and acceptable toxicity in pts with previously-treated advanced iCCA and FGFR fusions.
DOI:
10.1200/JCO.2023.41.16_suppl.e16118
Trial ID:
